"En lo que se refiere al tratamiento, además de las técnicas más avanzadas de radiología, HM CIOCC cuenta con la unidad de investigación traslacional, que posibilita un abordaje personalizado de cada tipo de tumor. Ejemplos de servicios de máximo nivel en este sentido son la Unidad de Radiología de la Mujer o el Servicio de Oncología Radioterápica, con tres aceleradores lineales -uno de ellos casi único en España, que permite hacer cirugía intra y extracraneal-, un quirófano inteligente y braquiterapia. HM CIOCC también cuenta con un área dedicada a investigación, tanto el Laboratorio de Dianas Terapéuticas como en el Servicio de Oncología Radioterápica."

During the past decade, Centro Integral Oncologico Clara Campal conducted 168 clinical trials. In the 10-year time frame, 168 clinical trials started and 68 clinical trials were completed, i.e. on average, 40.5% percent of trials that started reached the finish line to date. In the past 5 years, 68 clinical trials started and 51 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro Integral Oncologico Clara Campal" #1 sponsor was "Hoffmann-La Roche" with 69 trials, followed by "Genentech, Inc." with 14 trials sponsored, "Pfizer" with 8 trials sponsored, "Incyte Corporation" with 7 trials sponsored and "SOLTI Breast Cancer Research Group" with 7 trials sponsored. Other sponsors include 102 different institutions and companies that sponsored additional 74 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Integral Oncologico Clara Campal" #1 collaborator was "Breast International Group" with 5 trials as a collaborator, "Bristol-Myers Squibb" with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator and "Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud" with 2 trials as a collaborator. Other collaborators include 51 different institutions and companies that were collaborators in the rest 54 trials.

According to Clinical.Site data, the most researched conditions in "Centro Integral Oncologico Clara Campal" are "Breast Cancer" (21 trials), "Ovarian Cancer" (15 trials), "Solid Tumors" (14 trials), "Neoplasms" (9 trials) and "Colorectal Cancer" (8 trials). Many other conditions were trialed in "Centro Integral Oncologico Clara Campal" in a lesser frequency.

Most popular intervention types in "Centro Integral Oncologico Clara Campal" are "Drug" (191 trials), "Biological" (21 trials), "Other" (6 trials), "Genetic" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (33 trials), "Placebo" (24 trials), "Paclitaxel" (19 trials), "Bevacizumab" (17 trials) and "Gemcitabine" (15 trials). Other intervention names were less common.

The vast majority of trials in "Centro Integral Oncologico Clara Campal" are 176 trials for "All" genders, 29 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "Centro Integral Oncologico Clara Campal". undefined are not yet recruiting, 49 are recruiting, 31 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 101 completed trials in Centro Integral Oncologico Clara Campal, undefined suspended trials, and 22 terminated clinical trials to date.

Out of the total trials that were conducted in Centro Integral Oncologico Clara Campal, 86 "Phase 1" clinical trials were conducted, 82 "Phase 2" clinical trials and 60 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 3 trials that are defined as “Not Applicable".